Is the thymidine labeling index a good prognostic marker in breast cancer?
BACKGROUND
The aim of the present study was to determine the prognostic relevance of thymidine labeling index (TLI) in patients with breast cancer.


METHODS
TLI of the primary tumor was measured in 268 patients at the time of the surgical biopsy by an in vitro method.


RESULTS
Fifty-four patients had stage I disease, and 138 patients had stage II disease, and 76 patients had stage III disease. One hundred-four patients were found to have low TLI-index (<3%), and 164 patients had high TLI-index (>/=3%). The median follow-up was 71.5 months (range, 6-138 months). The 5-year overall survival (OS) and disease free survival (DFS) rates was 84% and 74%, respectively. Lymph node involvement, tumor size more than 2 cm, high nuclear grade and estrogen receptor negativity were found to be associated with poorer DFS and OS rates. On subgroup analysis, however, the 5-year OS rate was significantly higher in the low TLI-group than in the high TLI-group in patients with stage I disease (100% vs 76%, p = 0.05).


CONCLUSIONS
Our findings suggest that the prognostic significance of TLI appears to be limited to early breast cancer that might help to distinguish patients who need more aggressive adjuvant treatment.
Sen-Oran
Ebru
E
Departments of General Surgery, Istanbul Medical School, Istanbul University, Istanbul, Turkey. ebrusenoran@hotmail.com.
Ozmen
Vahit
V
Bilir
Ayhan
A
Cabioglu
Neslihan
N
Muslumanoglu
Mahmut
M
Igci
Abdullah
A
Guney
Nese
N
Kecer
Mustafa
M
Breast Cancer Res Treat. 2000 Oct;63(3):181-92
11110052
Breast Cancer Res Treat. 2001 Jul;68(2):147-57
11688518
Ann Surg. 2002 Jan;235(1):10-26
11753038
J Clin Oncol. 2002 Sep 1;20(17):3628-36
12202663
Br J Cancer. 1957 Sep;11(3):359-77
13499785
Cancer Res. 1992 Oct 1;52(19):5198-203
1394123
Am J Pathol. 2004 Jan;164(1):35-42
14695316
Am J Clin Oncol. 2004 Aug;27(4):400-6
15289735
N Engl J Med. 2004 Dec 30;351(27):2817-26
15591335
Eur J Cancer. 1992;28(2-3):424-6
1591056
N Engl J Med. 1992 Jun 25;326(26):1756-61
1594018
Breast Cancer Res. 2006;8(3):R25
16737553
J Clin Oncol. 1990 Aug;8(8):1321-6
2380758
Breast Cancer Res Treat. 1988 Oct;12(2):191-204
3242648
Cancer Treat Rep. 1987 Apr;71(4):375-9
3829014
Lab Invest. 1986 Jan;54(1):41-51
3941541
Int J Cancer. 1984 Apr 15;33(4):441-5
6706431
Cancer. 1981 Aug 15;48(4):974-9
7272939
J Clin Oncol. 1995 Mar;13(3):697-704
7884430
J Clin Oncol. 1993 Feb;11(2):351-9
8426213
Ann Oncol. 1993 Mar;4(3):213-9
8471553
Int J Cancer. 1999 Dec 22;84(6):580-6
10567902
Breast Cancer Res Treat. 1998;51(3):267-81
10068084
J Clin Oncol. 2000 Sep;18(17):3125-34
10963641
Int J Cancer. 2000 Jan 20;89(1):74-80
10719734
J Natl Cancer Inst. 1993 Jun 16;85(12):965-70
8496982
J Clin Oncol. 1993 Jun;11(6):1150-5
8501501
Cancer. 1995 Sep 15;76(6):1009-18
8625202
Int J Cancer. 1997 Feb 20;74(1):122-7
9036880
Anticancer Res. 1996 Nov-Dec;16(6C):3907-12
9042311